Dissecting India’s Healthtech
India's healthtech startups were growing rapidly even before the pandemic, but Covid-19 has ushered in a new age. This series dives into the trends, startups business models emerging in the wake of Covid-19.
In early May, a study published in the European Heart Journal said that while Covid-19 and the SARS CoV-2 virus infects a wide age group, it is predominantly seen in elderly individuals, especially men and those with cardiovascular disease. The study found that men have higher levels of the angiotensin-converting enzyme 2 (ACE2) in the blood, which helps the virus infect cells faster, thereby leaving men more vulnerable to the coronavirus.
The study was part of a diverse range of gene-centric research from across the world. Never before have the medical scientists of the world come together to fight something as one. But research takes time and scientific breakthroughs are much a result of trial and error as it is of brilliant minds.
“Because it is the first time [Covid-19], I think there have been a lot of missteps from everyone. A lot of resources have been drained out at all ends. I hope we can really take the learnings, document for the future and relook at the power centres,” says Anu Acharya.
The Mapmygenome cofounder recalls that even as India was only reading about the disease in January and February when the first cases were reported, the company decided to enter the preparation stage. “We told the team that we need to start preparing for and analysing our data to help our customers understand how to prevent themselves and build immunity from this virus,” added Acharya.